Announces completion of 1,5 Mio. Euro investment in continuation of its support of proven drugs using its high-compliance large-volume API capability with challenging chemistry and technology
Lodi, February 3, 2023.
Archimica has started the operation of its expanded large-volume, high-compliance Sucralfate API manufacturing capacity at its Lodi (Italy) site. The recent investment has further increased the company´s leading capacity by 50% to more than 500mt annually.
The expansion comprises major expansions to Archimica´s existing Sucralfate API facility, including doubling the drying capacity, expanded and upgraded de-dusting and segregation equipment. The expansion included the required quality and regulatory changes and was executed by Archimica´s experienced integrated team within less than 12 months from decision to supply. Archimica´s team seamlessly mastered the quality and technical product challenges, which include its insolubility with at the same time very low level of tolerable impurities, the required defined particle size distributions and the large volumes of highly challenging reagents to be used and recycled to the highest quality and environmental standards.
“Archimica being well-known for small to medium scale API manufacture, the expansion of our Sucralfate API capacity demonstrates our ability to manufacture large-volume APIs efficiently to the highest quality standards, adjust and expand our facilities with extraordinary agility and on time and target to the benefit of our customers and their drug supply requirements, as well as Archimica´s dedication to make proven standard care products available under the highest quality standards from our location in Italy, Europe. With this upgrade and after our more than 10 Mio. Euro investment in our development and manufacturing capabilities during the last 3 years, we are continuing our path to offer expanded state-of-the-art multi-step manufacturing options applying Archimica´s unique chemical reaction and technology portfolio to the benefit of our customers worldwide.”, said Ralf Pfirmann, Executive Chairman of Archimica.
Archimica is a leading organization specialized for more than 75 years in active pharmaceutical ingredients (APIs) development and manufacture for the benefit of customers and patients worldwide. Its site in Lodi, Italy operates in compliance with the most recent GMP guidelines and has been successfully inspected by US-FDA, AIFA and numerous other regulatory agencies.
Archimica’s experienced and flexible team, our broad permit and state-of-the-art environmental protection facilities enable us to industrialize products and processes with the most challenging reagents and reactions known with short lead times to accelerate drug development and supply for complex multi-step APIs into all clinical and commercial stages
Archimica employs more than 130 staff members which achieve annual revenues of more than 42 Mio. €. Since 2019 Archimica is a fully owned portfolio company of Livia Corporate Development SE.
For more information, visit https://www.archimica.com
Viale Milano, 86
26900 Lodi (LO), Italy